141 related articles for article (PubMed ID: 1921539)
1. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy.
Brody B; Wray N; Bame S; Ashton C; Petersen N; Harward M
Med Care; 1991 Sep; 29(9):899-910. PubMed ID: 1921539
[TBL] [Abstract][Full Text] [Related]
2. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
Lessler DS; Avins AL
Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
[TBL] [Abstract][Full Text] [Related]
3. Management of acute myocardial infarction 1990: a perspective.
Vogel JH
Clin Cardiol; 1991 Jan; 14(1):5-9. PubMed ID: 1902150
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
[TBL] [Abstract][Full Text] [Related]
5. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
Heyland DK; Gafni A; Levine MA
J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415
[TBL] [Abstract][Full Text] [Related]
6. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Goel V; Naylor CD
Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
[TBL] [Abstract][Full Text] [Related]
7. The choice of thrombolytic agents in the emergency department.
Langland-Orban B; Orban DJ
Ann Emerg Med; 1993 May; 22(5):845-51. PubMed ID: 8470843
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences for thrombolytic therapy in acute myocardial infarction.
Stanek EJ; Cheng JW; Peeples PJ; Simko RJ; Spinler SA
Med Decis Making; 1997; 17(4):464-71. PubMed ID: 9343805
[TBL] [Abstract][Full Text] [Related]
9. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
Shammas NW; Zeitler R; Fitzpatrick P
Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
[TBL] [Abstract][Full Text] [Related]
10. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
11. Overutilization and underutilization of thrombolysis in routine clinical practice.
Sleight P
J Am Coll Cardiol; 2001 May; 37(6):1588-9. PubMed ID: 11345369
[No Abstract] [Full Text] [Related]
12. Rural Alberta thrombolysis study. Survey of practice patterns for managing acute myocardial infarction.
Hindle H; Norheim JK; Renger R
Can Fam Physician; 1995 Jul; 41():1180-7. PubMed ID: 7647623
[TBL] [Abstract][Full Text] [Related]
13. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
[TBL] [Abstract][Full Text] [Related]
14. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
Tsui W; Pierre K; Massel D
Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
[TBL] [Abstract][Full Text] [Related]
15. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
Kellett J; Clarke J
Med Decis Making; 1995; 15(4):297-310. PubMed ID: 8544674
[TBL] [Abstract][Full Text] [Related]
16. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
[TBL] [Abstract][Full Text] [Related]
17. Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial.
Glasziou PP; Bromwich S; Simes RJ
Med J Aust; 1994 Nov; 161(9):532-6. PubMed ID: 7968752
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
Woo KS; White HD
Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
Lorenzoni R; Fattore G; Gensini G
G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
